U.S. to help Argentina reenter visa waiver program, DHS says
Argentina was part of the program between 1996 and 2002. The scheme allows citizens of certain countries to travel to the U.S. for business or tourism for up to 90 days without a visa, if their home nations meet counter-terrorism, law enforcement and immigration requirements.
Noem in a statement said that Argentina had the lowest visa overstay rate among Latin American countries, and that Argentine travel to the U.S. had been increasing.
She noted that Argentina had become an "even stronger friend" to the United States under President Javier Milei.
Libertarian Milei has sought to align himself with U.S. President Donald Trump, who has lauded Milei's deregulation efforts and called the Argentine leader his 'favorite president."
The DHS announcement comes shortly after Argentina decided to loosen visa requirements for Chinese visitors, saying those with valid U.S. entry visas would not need Argentine visas to enter the country for tourism or business.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
10 minutes ago
- Reuters
LG Innotek to take stake in lidar maker Aeva as part of $50 million deal
SAN FRANCISCO, July 29 (Reuters) - Aeva Technologies (AEVA.O), opens new tab said on Tuesday that South Korean camera module maker LG Innotek ( opens new tab will take an equity stake in Aeva as part of a $50 million strategic collaboration. Aeva makes lidar sensors that help vehicles and industrial equipment gain a detailed three-dimensional view of their environment and detect how fast surrounding objects are moving. It supplies sensors to vehicle firms such as Daimler Truck and industrial equipment makers such as Nikon. As part of the deal, LG Innotek will make a $32 million equity investment in Aeva for a "single-digit percentage ownership" in the company, Aeva CEO Soroush Salehian told Reuters in an interview. The remainder of the deal will go toward building production capacity for sensors that can go into robotics and consumer devices, in addition to Aeva's existing markets of vehicles and industrial equipment. 'The ultimate goal of this partnership is for LG Innotek and Aeva to grow together as key players leading the next-generation lidar market through a long-term technology partnership that goes beyond the supply of products,' the South Korean electronics supplier's CEO, Hyuksoo Moon, said in a statement. Salehian told Reuters that Aeva is working to integrate its entire sensor into a single chip whose price can be driven low enough to make it viable in consumer electronics such as augmented reality headsets. "The roadmap that we're going towards is double-digit dollars," Salehian told Reuters. "We are already working towards the next generation that will allow for a very low-cost solution, which we think will be a game changer for mass adoption of what we call precision sensing."
Daily Mirror
10 minutes ago
- Daily Mirror
Italian restaurant chain with 13 sites 'on brink of administration'
Sky News reports that Interpath Advisory is preparing a pre-pack insolvency, which is where the sale of a business or its assets is agreed before the administration begins Italian restaurant chain Gusto is reportedly on the brink of collapsing into administration. Sky News reports that Interpath Advisory is preparing a pre-pack insolvency, which is where the sale of a business or its assets is agreed before the administration process begins. Sky further claims that Cherry Equity Partners, the owner of Latin American restaurant concept Cabana, would likely takeover the majority of Gusto sites - but warned job losses were still expected. The Mirror has contacted Gusto for comment. Gusto has 13 UK restaurants including: Alderley Edge Birmingham Cheadle Hulme Cookridge Edinburgh Heswall Knutsford Leeds City Centre Liverpool Manchester Newcastle Nottingham Oxford Restaurant and pub owners have been struggling in recent years following the coronavirus pandemic and then the cost of living crisis. Increases in the minimum wage and National Insurance paid by employers have also added pressure onto hospitality businesses. BrewDog announced last week that it would shutter ten sites, including its flagship branch in Aberdeen. Its Camden branch closed on Friday, with the other bars closing from Saturday onwards. CEO James Taylor sent a message to all staff, explaining that the venues were no longer making money. He said: "Following much consideration, we have sadly concluded that there is no realistic prospect of making these venues commercially viable. "Keeping them open would put pressure on the wider business, making it harder to invest where we know we can grow. This decision is not simply a response to the challenging UK hospitality market, but a proactive decision to redefine the bar division's focus. "This is not a decision we've taken lightly. But as we evolve BrewDog into a more focused and sustainable business, we've had to be honest about where we are - and where we're heading." Meanwhile, Thai restaurant chain Busaba Eathai was brought out of administration last week as part of a pre-pack deal. It once had as many as 16 restaurants, but this was reduced to 12 following a Company Voluntary Arrangement (CVA) - which is a way for a struggling business to negotiate with creditors - in 2020. Joint administrator Neil Bennett said: 'Busaba has experienced tough trading conditions over the past few years, in line with the hospitality industry in general, including the negative consequences of the cost-of-living crisis, inflation and a substantial increase in utilities costs. 'The pre-pack sale has allowed us to transfer the business smoothly and has saved a long-standing London Thai restaurant along with hundreds of jobs." Oakman Inns & Restaurants also recently announced plans to close six sites and transfer a further 12 after falling into administration. Ross Connock, joint administrator at PwC, said: 'It's regrettable that six trading sites were not included in the sale, resulting in 159 redundancies. Our team of employee specialists are providing support to those affected during this challenging time.'
Reuters
10 minutes ago
- Reuters
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
July 29 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead (ARWR.O), opens new tab and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche (ROG.S), opens new tab had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March.
